Menu
Recruiting NCT07282483

Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients

Phase II Interventional Radiation-induced Oral Mucositis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Qingying oral liquid and modified Da Huang-Huang Lian Xiexin mouthwash, Placebo oral solution and mouthwash, radiotherapy.
Who it may be relevant to
Registry conditions: Radiation-induced Oral Mucositis. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients: A Randomized Controlled Trial

Overview

Evaluate the efficacy and safety of traditional Chinese medicine oral liquid and mouthwash in the treatment of radiotherapy induced oral mucositis in patients with head and neck malignancies

Detailed description

The aim of this clinical trial is to evaluate the efficacy and safety of combining a traditional Chinese medicine (TCM) oral liquid with a mouthwash in reducing the incidence, duration, and severity of mild-to-moderate radiation-induced oral mucositis (RIOM). The study addresses two main questions: (1) whether the combined TCM oral liquid and mouthwash can effectively mitigate RIOM and lower the incidence of severe RIOM, and (2) whether their use is associated with adverse events in patients receiving radiotherapy.

Participants will begin treatment on the first day mild-to-moderate RIOM (RTOG grade 1-2) occurs during radiotherapy. They will take Qingying oral liquid four times daily and use a modified Da Huang-Huang Lian Xiexin mouthwash six times daily in combination, or receive a matching placebo. The treatment will continue until two weeks after radiotherapy. After each administration, patients must avoid eating, drinking, or performing oral hygiene for at least 1 hour to maximize mucosal contact time.

The trial will compare the intervention and placebo groups to determine the potential benefits of the combined regimen for managing RIOM.

Interventions

  • Drug Qingying oral liquid and modified Da Huang-Huang Lian Xiexin mouthwash
    Classical traditional Chinese medicine (TCM) formulations provided as an oral liquid and a herbal mouthwash
  • Drug Placebo oral solution and mouthwash
    A placebo matched in color, odor, and taste to the Qingying oral liquid and the modified Da Huang-Huang Lian Xiexin mouthwash, but containing no active medicinal ingredients.
  • Radiation radiotherapy
    All subjects underwent radical radiotherapy

Primary outcome measures

  • Incidence rate of severe oral mucositis (RTOG grade ≥ 3) [Time frame: From the start of radiotherapy to 8 weeks after the end of radiotherapy. The evaluation period is approximately 14 to 14.5 weeks]
Secondary outcome measures (5)
  • Duration of mild-to-moderate RIOM [Time frame: From the start of radiotherapy to 8 weeks after the end of radiotherapy. The evaluation period is approximately 14 weeks and 14.5 weeks.]
  • The time to onset of any-grade oral mucositis (OM) [Time frame: From the start of radiotherapy to 8 weeks after completion of radiotherapy.The evaluation period is approximately 14 weeks and 14.5 weeks.]
  • RIOM remission rates at 4 and 8 weeks after completion of radiotherapy [Time frame: From the start of radiotherapy to 8 weeks after the end of radiotherapy. The evaluation period is approximately 14 weeks and 14.5 weeks.]
  • Duration of oral mucositis (OM) [Time frame: From the start of radiotherapy to 8 weeks after completion of radiotherapy.The evaluation period is approximately 14 weeks and 14.5 weeks.]
  • Adverse events [Time frame: From the first day of radiotherapy to the day of the last radiation dose received, usually 6 or 6.5 weeks.]

Eligibility criteria

Inclusion criteria

  • Patients pathologically diagnosed with non-metastatic head and neck malignant tumors;
  • Age range: 18 to 65 years old (including 18 and 65 years old);
  • Eastern Cooperative Oncology Group performance status of ≤2;
  • Radiotherapy or concurrent chemoradiotherapy is required;
  • The main organ functions well;
  • Sign informed consent.

Exclusion criteria

  • Allergic constitution (such as those known to be allergic to two or more drugs);
  • Patients who plan to use drugs that can cause or worsen oral mucosal inflammation (such as anti EGFR monoclonal antibodies, immune checkpoint inhibitors, etc.) after the start of radiotherapy;
  • Use of antibiotics, antifungal drugs, or antimicrobial mouthwash within 1 month of the study;
  • Poor oral hygiene and/or severe periodontal diseases;
  • History of head and neck radiotherapy;
  • Deemed unsuitable for the study by the investigators (concomitant with any other severe diseases).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

China · 1 center
  • West China Hospital — Chengdu

Identifiers

NCT: NCT07282483 · 2024-1774

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗